These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25651450)

  • 1. Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration.
    Manresa N; Mulero J; Losada M; Zafrilla P
    J Nutr Health Aging; 2015 Feb; 19(2):228-31. PubMed ID: 25651450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Manresa N; Mulero J; Losada M; Zafrilla P
    Retina; 2015 Sep; 35(9):1765-71. PubMed ID: 25923955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
    Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
    Matthé E; Sandner D
    Ophthalmologe; 2011 Apr; 108(4):337-41. PubMed ID: 21181168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
    Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
    Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
    Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
    Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegaptanib for wet macular degeneration.
    Fraunfelder FW
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
    Vedula SS; Krzystolik MG
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005139. PubMed ID: 18425911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration.
    Oishi A; Mandai M; Nishida A; Hata M; Matsuki T; Kurimoto Y
    Eur J Ophthalmol; 2011; 21(6):777-82. PubMed ID: 21500186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM; Costa R; Falcão MS; Barthelmes D; Mendonça LS; Fonseca SL; Gonçalves R; Gonçalves C; Falcão-Reis FM; Soares R
    Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.